论文部分内容阅读
目的:探究氯沙坦与贝那普利联合治疗肾实质性高血压的临床价值。方法:将该院收治的肾实质性高血压患者分为对照组和观察组。对照组接受贝那普利进行治疗,观察组则接受氯沙坦与贝那普利的联合治疗。结果:观察组收缩压、舒张压、24 h尿蛋白及血肌酐均低于对照组(P<0.05);两组不良反应率无明显差异(P>0.05)。结论:氯沙坦与贝那普利联合治疗肾实质性高血压具有良好的降压、降低尿蛋白的作用,具有安全性与疗效性,值得推广。
Objective: To investigate the clinical value of losartan and benazepril in the treatment of renal parenchymal hypertension. Methods: The hospitalized patients with renal parenchymal hypertension were divided into control group and observation group. The control group received benazepril treatment, the observation group received losartan and benazepril combination therapy. Results: Systolic blood pressure, diastolic blood pressure, 24 h urinary protein and serum creatinine in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Losartan combined with benazepril treatment of renal parenchymal hypertension has good antihypertensive effect, reduce the role of urinary protein, with safety and efficacy, it is worth promoting.